drugset / Trial / NCT04151472

Idebenone for the Preventive Treatment of Migraine

NCT04151472

RandomizedParallel-groupQuadruple-blindTreatment

Summary

Idebenone improves energy metabolism similarly to Coenzyme Q10, which is effective in migraine prophylaxis. The investigators compare idebenone (90 mg/day, 270 mg/day) and placebo in 180 migraine patients in a double-blind, randomized, placebo-controlled, multicenter trial to study whether Idebenone is superior to placebo in the prevention of episodic migraine with or without aura.

Timeline

Start
2021-12-08
Primary completion
2025-12-31
Completion
2025-12-31

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Idebenone Small molecule 90 mg Oral
Subject Idebenone Small molecule 270 mg Oral

Indications